Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02914509 | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT | PHASE3 | COMPLETED | 565 | — | — | Nov 7, 2016 | Mar 30, 2019 | Oct 11, 2021 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| OTX-TP (sustained release travoprost) Intracanalicular Depot | EXPERIMENTAL | OTX-TP (sustained release travoprost) Intracanalicular Depot |
| PV (Placebo Vehicle) Intracanalicular Depot | PLACEBO_COMPARATOR | PV (Placebo Vehicle) Intracanalicular Depot |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | - |
| Placebo Vehicle | OTHER | - |
Inclusion Criteria: * Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession * IOP is currently controlled as assessed by the Investigator Exclusio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |